The effect of α-blocker therapy on erectile functions in patients with lower urinary tract symptoms due to benign prostate hyperplasia

Asian Journal of Andrology

Volumn 11, Issue 6, 2009, Pages 716-722

  Demir, Omer ^a   Ozdemir, Ismail ^a   Bozkurt, Ozan ^a   Aslan, Guven ^a   Esen, Ahmet Adil ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

DOXAZOSIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; ERECTILE DYSFUNCTION; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; INTERNATIONAL INDEX OF ERECTILE FUNCTION INTERCOURSE SATISFACTION; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PREVALENCE; PROSTATE HYPERTROPHY; QUALITY OF LIFE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; DOXAZOSIN; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; PENILE ERECTION; PROSTATIC HYPERPLASIA;

EID: 71049144375     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2009.58     Document Type: Article

References (25)

1. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469-71.
2. Aslan G, Cavus E, Karas H, Oner O, Duran F, et al. Association between lower urinary tract symptoms and erectile dysfunction. Arch Androl 2006; 52: 155-62.
3. Girman CJ, Jacobsen SJ, Tsukamoto T, Richard F, Garraway WM, et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998; 51: 428-36.
4. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, et al. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004; 46: 547-54.
5. Chapple CR. Selective a1-adrenoceptor antagonists in benign prostatic hyperplasia: Rationale and clinical experience. Eur Urol 1996; 29: 129-44.
6. Gillenwater JY, Conn RL, Chrysant SG, Roy J, Gaffney M, et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension. A double-blind, placebocontrolled, doseresponse multicenter study. J Urol 1995; 54: 110-5.
7. Kirby RS, Andersen M, Gratzke P, Dahlstrand C, Høye K. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU Int 2001; 87: 192-200.
8. Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Latest update on α1-adrenoceptor antagonists. BJU Int 2005; 95: 29-36.
9. Michel MC, Mehlburger L, Schumacher H, Bressel HU, Goepel M. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Urol 2000; 163: 1725-9.
10. Hammarsten J, Högstedt B, Holthuis N, Mellström D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998; 1: 157-62.
11. McVary K. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005; 47: 838-45.
12. Berger AP, Bartsch G, Deibl M, Alber H, Pachinger O, et al. Atherosclerosis as a risk factor for benign prostatic hyperplasia. BJU Int 2006; 98: 1038-42.
13. De Rose AF, Carmignani G, Corbu C, Giglio M, Traverso P, et al. Observational multicentric trial performed with doxazosin. Evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia. Urol Int 2002; 68: 95-8.
14. Traish A, Kim NN, Moreland RB, Goldstein I. Role of alpha adrenergic receptors in erectile function. Int J Impot Res 2000;12 (Suppl 1): S48-63.
15. Seo KK, Lee MY, Lim SW, Kim SC. Comparison of relaxation responses of cavernous and trigonal smooth muscles from rabbits by alpha1-adrenoceptor antagonists; prazosin, terazosin, doxazosin, and tamsulosin. J Korean Med Sci 1999; 14: 69-74.
16. Demir O, Murat N, Aslan G, Gidener S, Esen A. Effect of doxazosin with and without rho-kinase inhibitor on human corpus cavernosum smooth muscle in the presence of bladder outlet obstruction. J Urol 2006; 175: 2345-9.
17. Kushiro T, Takahashi A, Saito F, Otsuka Y, Soma M, et al. Erectile dysfunction and its influence on quality of life in patients with essential hypertension. Am J Hypertens 2005; 18: 427-30.
18. Hoesl CE, Woll EM, Burkart M, Altwein JE. Erectile dysfunction (ED) is prevalent, bothersome and underdiagnosed in patients consulting urologists for benign prostatic syndrome (BPS). Eur Urol 2005; 47: 511-7.
19. Althof SE, Cappelleri JC, Shpilsky A, Stecher V, Diuguid C, et al. Treatment responsiveness of the self-esteem and relationship questionnaire in erectile dysfunction. Urology 2003; 61: 888-92.
20. Mulhall JP, Guhring P, Parker M, Hopps C. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006; 3: 662-7.
21. Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007; 51: 1485-7.
22. Kang KK, Kim JM, Yu JY, Ahn BO, Yoo M, et al. Effects of phosphodiesterase type 5 inhibitor on the contractility of prostate tissues and urethral pressure responses in a rat model of benign prostate hyperplasia. Int J Urol 2007; 14: 946-51.
23. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98.
24. Okada H, Kamidono S, Yoshioka T, Okuyama A, Ozono S, et al. A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients. BJU Int 2000; 85: 676-81.
25. Wu CJ, Hsieh JT, Lin JS, Hwang TI, Jiann BP, et al. Comparison of prevalence between self-reported erectile dysfunction and erectile dysfunction as defined by five-item International Index of Erectile Function in Taiwanese men older than 40 years. Urology 2007; 69: 743-7.